Biological Shipping Blog, Cold Chain Transport Blog

4 Capabilities that Support a Superior Condition Monitoring Solution

How Our Requalification Process Maintains Material Integrity

A Glance into Our Houston & Morris Plains Global Supply Chain Centers

3 Services Your Biopharmaceutical Supply Chain Partner Should Offer

Exclusive Q&A with Bruce McAfee, Director of BioServices Commercial Support

Innovation and Risk Mitigation are Priorities for Cell&Co BioServices

State of the Industry: 2023 Predictions with Dr. Mark Sawicki

Documentary: Cell & Gene Therapy - Advancing The Next Generation of Pharmaceuticals

Through Our Newly Launched Global Supply Chain Centers, Cryoport Systems Now Offers Kit Production

Cryoport's Chain of Compliance®: Collects, Interprets, and Leverages Comprehensive Data to Enable a Significantly Smarter Supply Chain

Cryoshuttle® Local Delivery and Pickup: Now Serving More Areas

The Cryoport Way: A Leap Forward in Standardizing the Regenerative Medicine Supply Chain

Cryoport Systems’ Global BioServices: Secondary Packaging and Labeling Solutions

The Untapped Potential for Cord Blood as Allogeneic Starting Material

Cryoport Systems Global Supply Chain Center: Ready for Launch!

New Product Launch: The Latest Enhancements to Cryoport Express® Standard & Combo Cryogenic Shippers

Are You Ready for the Upcoming Data Network Transition? Here's Everything You Need to Know

2022 Updates to the Harmonized System (HS) and Harmonized Tariff Schedule (HTS)

Cryoport Systems & CRYOPDP Synergies Provide Integrated and Flexible Temperature-Controlled Supply Chain Solutions for the Life Sciences

Introducing Cryoport BioServices in Morris Plains, NJ ─ A Strategic & Prime Location for Supporting the Life Sciences

Courier Agnostic – Cryoport Systems’ Great Advantage

Introducing Cryoport BioServices: Providing a Stronger, Smarter Supply Chain Worldwide

More Commercial Activity, More Commercial Filings: Good News Ahead for Regenerative Medicine

Forbes Honors Cryoport, Inc. on 2021 ‘100 Best Small Companies’ List

Now That A Brexit Deal Has Been Negotiated, Here Is What Cryoport Clients Can Expect

Cryoport Client Informational Bulletin: Brexit

Cryoport, Inc. By The Numbers: A Year of Record Expansion in 2020

What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers

Coronavirus Update: Proactive measures we continue to take

Is Your Supply Chain Partner ISO 9001:2015 Certified? Here’s Why Certification Matters

How the World’s Biggest Biopharma Companies Manage Increasingly Complex Supply Chain Demands

Cryoport Just Signed Agreements to Acquire MVE Biological Solutions and CRYOPDP. Here’s What’s Next.

Our Success Is Your Success: Cryoport Marks Milestones While Supporting Clients Through the Pandemic

Navigating the New Normal in the Transportation Industry as the Pandemic Continues

How the Coronavirus Pandemic Is Impacting Global Shipping and Logistics – And How Cryoport Can Help

New FDA Guidelines on Gene Therapy IND Process A Significant Step Forward

2019: The Year of Cryoport Milestones

Avoiding Catastrophe: Addressing the Supply Chain Risks in Cell and Gene Therapy Development

As Cell Therapy Approvals Speed Up, Companies Struggle with Manufacturing Demands

Biostorage: A Critical Component of the Medical Research Development Process

When Failure Isn’t an Option, Trust the Supply Chain Partners with a Proven and Successful Track Record

Scientific Innovation is Messy. Cryoport is The Reliable Logistics Provider for the Cell and Gene Therapy Trial Process

Cell and Gene Therapy Success Depends on Mastering the New Needs of the Supply Chain: Dispatch from the Shanghai CAR-T Summit

Growing with Our Clients: New Cryoport Innovations Help Support Commercial Gene Therapies and Nearly 400 Clinical Trials

With More Than 200 Cell and Gene INDs on File with FDA by 2020, Challenges Lie Ahead on Path to Approval

Cryoport Rings Nasdaq Closing Bell

As the Regenerative Medicine Industry Grows, A Complete Support System Is More Critical Than Ever

Learn About Cryoport’s Latest Innovations at the 2019 World Advanced Therapies and Regenerative Medicine Congress and Expo in London

Unpacking the Physics of Cryoport’s Certified, Cool 2-8°C Shipper for Fresh Biospecimen Transportation

What’s Next For Regenerative Medicine: Regulations—Lots of Regulations

Can you Afford to Not Consider the Importance of Informatics in Your Global Temperature Controlled Supply Chain?

Risk Mitigation in Clinical Trials

Why "Wait and See" Isn't an Option

Shipping Validations are Common Shipping New Pharmaceutical Products - But Who ‘Validates’ the Carriers? Cryoport Can!

Ensure Chain of Compliance® in Your Supply Chain

How to Prevent Damage to Biomaterials During Shipment

FDA’s Recent Outlook and New Policies for Cell and Gene Therapies

Why Evaporative Cooling Shippers Are Not Optimal for Pharmaceutical Applications in the 2-8°C Range

Can You Ship Biological Samples Currently Stored or Shipped with Dry Ice (-0 to -80°C) in Cryoport’s Dry Vapor Shipper at -150°C?

What Do You Know About Your Dry Vapor Shipper and its Potential Impact on your Critical Materials?

The Critical Need for the End to End Data Flows for Regenerative Therapies

Beyond Logistics – What’s Needed for Successful Support of Clinical Trials and Commercialization in Regenerative Medicine?

Transportation Safety: Same and Different Across Countries

The Emergence of Chain of Compliance®

Are You Securing “Smooth” Compliant Movement of Your Biological Materials?

Compliance Considerations Driving Temperature-Controlled Logistics

Cryoport’s Temperature Controlled Logistics Solutions Supporting Regenerative Medicine Advanced Therapy (RMAT) Clinical Development

Scientific Conclusions Are All About the Data--Choosing a Logistics Provider For Biomaterial Transport Should Be As Well

Considerations for Successful Biomaterial Transport into Challenging Countries

Transporting Life: A Journey of Choice

Dry Vapor: The Hero for the Ever-Growing CO2 Shortage

Cryoport is the Complete Logistics Solution for Your Clinical Programs

Cryoport Practices Quality by Design (QbD) Approaches When Developing New Products and Processes

Cancer MoonShot 2020 Initiative Spurs Immunotherapy Research and Integrated Logistics Need

Cold Chain Solutions for Autologous Cell Therapy Commercialization

Using Real-World Data to Reduce Cold Chain Risk

Outsourcing Dewar Management to Improve Human and Animal Health Operations

Cryoport Now Supports Laboratory Relocation

Helping Hospitals Unmask Cancer

Notes From The Field – Minimizing Cold Chain Risk for Regenerative Medicines

Cryoport Allows Yancey Farms to Meet Peak Demand During Breeding Season

The Top 5 Hidden Costs of Dry Ice Shipping

Cryoport, the Company Behind the Technology used in the FedEx® Deep Frozen Shipping Solution

Cryoport^® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC